Pharmacogenetic of donepezil for Alzheimer's disease treatment
Article Sidebar
Main Article Content
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195-203.
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75.e2.
Madnani RS. Alzheimer's disease: a mini-review for the clinician. Front Neurol. 2023;14:1178588. doi: 10.3389/fneur.2023.1178588.
Neurological Institute of Thailand. Clinical Practice Guidelines for Dementia 2020. Bangkok: Neurological Institute of Thailand; 2021. Thai.
Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet. 2013;52(4):225-41.
Yu JT, Tan L, Hardy J. Apolipoprotein E in Alzheimer's disease: an update. Annu Rev Neurosci. 2014;37:79-100.
Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421-30.
Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333-44.
Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106-18.
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-3.
Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 2011;10(3):241-52.
Liu M, Bian C, Zhang J, Wen F. Apolipoprotein E gene polymorphism and Alzheimer's disease in Chinese population: a meta-analysis. Sci Rep. 2014;4:4383.
Wu P, Li HL, Liu ZJ, Tao QQ, Xu M, Guo QH, et al. Associations between apolipoprotein E gene polymorphisms and Alzheimer's disease risk in a large Chinese Han population. Clin Interv Aging. 2015;10:371-8.
Senanarong V, Harnphadungkit K, Lertrit P, Mitrpant C, Udompunthurak S, Limwong C, Prayoonwiwat N, Poungvarin N. Experience of ApoE study in Thai elderly. J Med Assoc Thai. 2001;84(2):182-7.
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349-56.
Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489-95.
Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet. 2012;27(1):55-67.
Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry. 2013;25(5):534-53.
Varsaldi F, Miglio G, Scordo MG, Dahl ML, Villa LM, Biolcati A, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol. 2006;62(9):721-6.
Zhong Y, Zheng X, Miao Y, Wan L, Yan H, Wang B. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease. Am J Med Sci. 2013;345(3):222-6.
Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci. 2007 Sep;96(9):2224-31.
Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60(2):284-95.
Lu J, Fu J, Zhong Y, Chen P, Yang Q, Zhao Y, et al. The roles of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer's disease. Neurosci Lett. 2016;614:43-8.
Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009;73(10):761-7.
Klimkowicz-Mrowiec A, Wolkow P, Sado M, Dziubek A, Pera J, Dziedzic T, et al. Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer's disease. Neuropsychiatr Dis Treat. 2013;9:1029-33.
Liu M, Zhang Y, Huo YR, Liu S, Liu S, Wang J, et al. Influence of the rs1080985 single nucleotide polymorphism of the CYP2D6 gene and APOE polymorphism on the response to donepezil treatment in patients with Alzheimer's Disease in China. Dement Geriatr Cogn Disord Extra. 2014;4(3):450-6.
Seripa D, Bizzarro A, Pilotto A, D'Onofrio G, Vecchione G, Gallo AP, et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenet Genomics. 2011;21(4):225-30.
Albani D, Martinelli Boneschi F, Biella G, Giacalone G, Lupoli S, Clerici F, et al. Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients. J Alzheimers Dis. 2012;30(4):745-9.
Liu M, Zhang Y, Huo YR, Liu S, Liu S, Wang J, et al. Influence of the rs1080985 single nucleotide polymorphism of the CYP2D6 gene and APOE polymorphism on the response to donepezil treatment in patients with Alzheimer's disease in China. Dement Geriatr Cogn Disord Extra. 2014;4(3):450-6.
Sonali N, Tripathi M, Sagar R, Velpandian T, Subbiah V. Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2014;37(1-2):58-70.
Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon Aet al. Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. Br J Clin Pharmacol. 2014;78(1):135-44.
Lu J, Wan L, Zhong Y, Yu Q, Han Y, Chen P, et al. Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. J Pharmacol Sci. 2015 Nov;129(3):188-95.
Chianella C, Gragnaniello D, Maisano Delser P, Visentini MF, Sette E, Tola MR, et al. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol. 2011;67(11):1147-57.
Yaowaluk T, Senanarong V, Limwongse C, Boonprasert R, Kijsanayotin P. Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer's disease and vascular dementia. Pharmgenomics Pers Med. 2019;12:209-24.
Magliulo L, Dahl ML, Lombardi G, Fallarini S, Villa LM, Biolcati A, et al. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol. 2011;67(1):47-54.
Sun H, Lv C, Zhang X, Sun X, Chen S, Li K, et al. Association of CHAT Gene Polymorphism rs3793790 and rs2177370 with Donepezil Response and the Risk of Alzheimer's Disease Continuum. Clin Interv Aging. 2024;19:1041-50.